NCT06844110

Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Malignant Tumor

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

68Ga-DOTA-dPNE PET/CT imaging was performed on patients with malignant tumors to observe the binding of lesions with the tracer and evaluate the expression of CD73. At the same time, correlation analysis was performed combined with relevant clinical indicators to evaluate the efficacy of 68Ga-DOTA-dPNE in the diagnosis and guidance of malignant tumor patients, and predict the response of targeted therapy.

Conditions

• Tumor Immunity

Interventions

Type	Name	Description
DRUG	68GA-DOTA-dPNE	Intravenous administration of 68GA-DOTA-dPNE tracer

Timeline

• Start date: 2025-03-01
• Primary completion: 2025-12-30
• Completion: 2026-03-30
• First posted: 2025-02-25
• Last updated: 2025-08-05

Locations

1 site across 1 country: China